Download PDF
Onkologische Welt 2011; 02(06): 291-292
DOI: 10.1055/s-0038-1632133
Kongressnachlese multidisziplinär
Schattauer GmbH

Metastasiertes Kolonkarzinom: Stetiger Anstieg der Lebenserwartung in den vergangenen 10 Jahren

Peter Henning Dr.
Further Information

Publication History

Publication Date:
31 January 2018 (online)

Also available at
    Permissions and Reprints

Das Gesamtüberleben von Patienten mit mCRC ist in der vergangenen Dekade von 12,6–17,4 Monaten im Jahr 2000 auf 22,8-23,9 Monate im Jahr 2011 gestiegen und hat sich somit sukzessive verdoppelt, erläuterte Prof. Jean-Yves Douillard, Saint-Herblain, Frankreich.

 

  • Literatur

  • 1 Douillard JY. et al. Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts.. J Clin Oncol 2011; 29: 3510.
    CrossrefPubMedSearch in Google Scholar
  • 2 Douillard JY. et al. Safety of panitumumab (pmab) in combination with chemotherapy (ct) from five clinical trials in 812 patients (pts) with metastatic colorectal cancer (mCRC) and wild-type (WT) KRAS tumors. ASCO-GI 2010; Abstract Nr. 409.
  • 3 Peeters M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.. J Clin Oncol 2010; 28: 4706-4713 DOI:10.1200/JCO.2009.27.6055.
    CrossrefPubMedSearch in Google Scholar
  • 4 Price TJ. et al. Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). ASCO Meeting Abstracts.. J Clin Oncol 2010; 28 (Suppl. 15) 3529.
    CrossrefSearch in Google Scholar
  • 5 Peeters M. et al. Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. ASCO Meeting Abstracts.. J Clin Oncol 2011; 29: 3574.
    CrossrefPubMedSearch in Google Scholar
  • 6 Price TJ. et al. Efficacy of panitumumab plus FOLFI-RI versus FOLFIRI alone in patients with wild-type (wt) KRas metastatic colorectal cancer (mCRC) treated with prior oxaliplatin or bevacizumab regimes: Results from 20050181. ECCO16-ES-MO36-ESTRO30 Abstracts Nr. 6132.. EJC 2011; 47 (Suppl. 01) S431-S432.
    Search in Google Scholar
  • 7 Seymour MT. et al. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition 29 (15) suppl (May 20 Supplement 2011; 3523.
    Search in Google Scholar